TCL Archive Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response November 29, 2013
TCL Archive Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now December 2, 1983
TCL Archive FDA, NCI Remain At Odds Over Drug approval Guidelines Despite Reconciliation Discussion October 9, 1987
TCL Archive Also in this issue: ODAC Votes To Strip Breast Cancer Indication From Avastin July 23, 2010
TCL Archive New CEO Brings Managed Care Expertise To Network Of Academic Cancer Centers January 24, 1997
